Design Therapeutics, Inc.
NASDAQ:DSGNBiotechnology
+$0.19 today
- Market cap
- $606.42M
- Beta
- 1.66
- P/E (TTM)
- -10.7
- EPS (TTM)
- -$1.13
Volume 0.32M
Average 0.74M
DSGN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Design Therapeutics, Inc.NASDAQ: DSGN
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development dips below year-ago levels
Q1 FY2026 research & development of $14.38M fell 6.5% year over year, behind the +16.8% change in trailing-twelve-month research & development. Sequentially, it rose 7.1% from the prior quarter. Over 3 fiscal years it compounded at +6.7% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -6.5% toward the trailing-twelve-month pace of +16.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 59.13M USD
- Year-over-year change
- +33.3%
- 4-year CAGR
- +24.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 59.13M | +33.3% |
| FY2024 | 2024-12-31 | 44.35M | -22.3% |
| FY2023 | 2023-12-31 | 57.06M | +17.4% |
| FY2022 | 2022-12-31 | 48.61M | +96.2% |
| FY2021 | 2021-12-31 | 24.78M | — |
Research & Development vs competitors
How DSGN compares with its peers on the latest reported figures
- DSGN's LTM Mar 2026 research & development of $58.13M is the 10th highest of the 11 companies compared; the peer median is $172.57M.
- Its year-over-year change of +16.8% is the 5th highest of 11, against a peer median of +9.2%.
- Over three fiscal years its annual growth of +6.7% compares with a peer median of +18.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $923.16M | +4.7% | +3.2% | 96.2% | |
| LTM Mar 2026 | $902.58M | -34.5% | +20.2% | 41.3% | |
| LTM Jun 2026 | $445.71M | +17.2% | +40.8% | — | |
| LTM Jun 2026 | $433.31M | -14.7% | -11.3% | 43.0% | |
| LTM Mar 2026 | $189.6M | +13.6% | +16.4% | 264.1% | |
| LTM Mar 2026 | $155.55M | +43.4% | +21.4% | — | |
| LTM Mar 2026 | $152.7M | +75.7% | +85.3% | — | |
| LTM Mar 2026 | $144.07M | +45.7% | +21.0% | 449.1% | |
| LTM Mar 2026 | $58.35M | -32.7% | +9.5% | — | |
| LTM Mar 2026 | $58.13M | +16.8% | +6.7% | — | |
| LTM Mar 2026 | $56.78M | +0.2% | -9.9% | — | |
| Peer median (excluding DSGN) | $172.57M | +9.2% | +18.3% | 96.2% | |
Competitors are the stored peer set for DSGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 466K | 537K | 596K | 622K |
| Gross Profit | 0 | (466K) | (537K) | (596K) | (622K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 24.78M | 48.61M | 57.06M | 44.35M | 59.13M |
| Selling, General & Admin | 11.05M | 18.98M | 21.13M | 18.03M | 20.34M |
| Operating Expenses | 35.83M | 67.13M | 77.65M | 61.79M | 78.85M |
| Depreciation & Amortization | 129K | 466K | 537K | 596K | 622K |
| EBITDA | (35.4M) | (62.84M) | (66.33M) | (48.99M) | (69.17M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (35.83M) | (67.59M) | (78.19M) | (62.38M) | (79.47M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 12.8M | 9.68M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 298K | 4.29M | 11.33M | 12.8M | 9.68M |
| Income Before Tax | (35.53M) | (63.31M) | (66.86M) | (49.59M) | (69.79M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (35.53M) | (63.31M) | (66.86M) | (49.59M) | (69.79M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.77) | (1.14) | (1.19) | (0.88) | (1.22) |
| EPS (Diluted) | (0.77) | (1.14) | (1.19) | (0.88) | (1.22) |
| Weighted Avg Shares | 45.94M | 55.71M | 55.98M | 56.59M | 57.33M |
| Weighted Avg Shares (Diluted) | 45.94M | 55.71M | 55.98M | 56.59M | 57.33M |
Design Therapeutics, Inc.
NASDAQ:DSGN
Intrinsic Alpha fair value
Locked
Current Price
$9.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.